169 related articles for article (PubMed ID: 35150339)
1. Oncotype DX testing does not affect clinical practice in stage IIa colon cancer.
Allar BG; Messaris E; Poylin VY; Schlechter BL; Cataldo TE
Med Oncol; 2022 Feb; 39(5):59. PubMed ID: 35150339
[TBL] [Abstract][Full Text] [Related]
2. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
[TBL] [Abstract][Full Text] [Related]
3. Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.
You YN; Rustin RB; Sullivan JD
Surg Oncol; 2015 Jun; 24(2):61-6. PubMed ID: 25770397
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
Brenner B; Geva R; Rothney M; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Gluzman A; Purim O; Shacham-Shmueli E; Shulman K; Mishaeli M; Man S; Soussan-Gutman L; Tezcan H; Chao C; Shani A; Liebermann N
Value Health; 2016 Jan; 19(1):82-7. PubMed ID: 26797240
[TBL] [Abstract][Full Text] [Related]
5. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
6. Oncotype DX
Pease AM; Riba LA; Gruner RA; Tung NM; James TA
Ann Surg Oncol; 2019 Feb; 26(2):366-371. PubMed ID: 30542840
[TBL] [Abstract][Full Text] [Related]
7. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
[TBL] [Abstract][Full Text] [Related]
8. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
9. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
11. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
12. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
13. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
14. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
[TBL] [Abstract][Full Text] [Related]
15. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
Yun HR; Kim HC; Yun SH; Lee WY
Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
[TBL] [Abstract][Full Text] [Related]
17. Preoperative prognostic nutritional index predicts risk of recurrence after curative resection for stage IIA colon cancer.
Maruyama T; Shimoda M; Hakoda H; Sako A; Ueda K; Suzuki S
Am J Surg; 2021 Jul; 222(1):179-185. PubMed ID: 33138968
[TBL] [Abstract][Full Text] [Related]
18. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
19. Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study.
Oki E; Watanabe J; Sato T; Kagawa Y; Kuboki Y; Ikeda M; Ueno H; Kato T; Kusumoto T; Masuishi T; Yamaguchi K; Kanazawa A; Nishina T; Uetake H; Yamanaka T; Yoshino T
ESMO Open; 2021 Jun; 6(3):100146. PubMed ID: 33984677
[TBL] [Abstract][Full Text] [Related]
20. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Joh JE; Esposito NN; Kiluk JV; Laronga C; Lee MC; Loftus L; Soliman H; Boughey JC; Reynolds C; Lawton TJ; Acs PI; Gordan L; Acs G
Oncologist; 2011; 16(11):1520-6. PubMed ID: 22016474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
